OncoMatch/Clinical Trials/NCT06508463
Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
Is NCT06508463 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies multiple treatments including Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter and Cemiplimab for peripheral t cell lymphoma.
Treatment: Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter · Cemiplimab · Ruxolitinib — This phase I trial studies the best dose and side effects of recombinant vesicular stomatitis virus (VSV) carrying the human (h) sodium iodide symporter (NIS) and Interferon (IFN) beta (β) genes (VSV-hIFNβ-NIS) in combination with cemiplimab in patients with T-cell lymphoma. A virus, called VSV-hIFNβ-NIS, which has been changed in a certain way, may be able to kill cancer cells without damaging normal cells. Immunotherapy with ipilmumab and cemiplimab may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Other
Cancer type
Non-Hodgkin Lymphoma
Disease stage
Required: Stage RELAPSED, REFRACTORY
Relapsed or refractory; ...Measurable disease by CT or magnetic resonance imaging (MRI): must have at least one lesion that has a single diameter of > 2 cm or tumor cells in the blood > 5 x 10^9/L; NOTE: skin lesions can be used if the area is > 2 cm in at least one diameter and photographed with a ruler and the images are available in the medical record
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational
Exception: topical emollients or corticosteroids, acetic acid soaks, etc. to control pruritus and prevent infection allowed in TCL; no topical chemotherapy is allowed (no topical nitrogen mustard)
Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (used for a non-Food and Drug Administration [FDA] approved indication and in the context of a research investigation); NOTE: in TCL, patients may use topical emollients or corticosteroids, acetic acid soaks, etc. to control pruritus and prevent infection; no topical chemotherapy is allowed (no topical nitrogen mustard)
Lab requirements
Blood counts
Absolute Neutrophil Count (ANC) ≥ 1,000/μL; Platelets ≥ 100,000/μL; Hemoglobin ≥ 8.5 g/dl
Kidney function
Creatinine ≤ 2.0 mg/dL
Liver function
ALT and AST ≤ 2 times upper limit of normal (ULN); Direct bilirubin ≤ 1.5 x ULN; If baseline liver disease, Child Pugh score not exceeding class A
ALT and AST ≤ 2 times upper limit of normal (ULN); Creatinine ≤ 2.0 mg/dL; Direct bilirubin ≤ 1.5 x ULN; INR/PT and aPTT ≤ 1.5 x ULN; If baseline liver disease, Child Pugh score not exceeding class A; Absolute Neutrophil Count (ANC) ≥ 1,000/μL; Platelets ≥ 100,000/μL; Hemoglobin ≥ 8.5 g/dl
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic in Arizona · Scottsdale, Arizona
- Mayo Clinic in Rochester · Rochester, Minnesota
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06508463 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational disqualifies patients from enrollment.
What disease stage is eligible?
Stage RELAPSED or REFRACTORY is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages